Calluna Pharma AS, a developer of antibodies to treat inflammatory and fibrotic diseases, has appointed Mark Gaffney as chief executive officer and Mark Altmeyer as chair of the board. Calluna’s interim CEO John Montana will return to his role as an operating partner at Forbion, which led a €75 million Series A financing round in early 2024 to support the launch of the Norway-based company. It was created from a merger of Oxitope Pharma BV of the Netherlands and Arxx Therapeutics AS of Norway. The executive appointments come amid the expected completion in 2024 of a Phase 1 programme for Calluna’s lead candidate, CAL101. Mr Gaffney brings over 20 years of experience in biotech and was most recently CEO of Oxular Limited where he remains on the board. Mr Altmeyer is currently chair of AM-Pharma and is also on the boards of Novaremed, Merz Therapeutics, Aculys, and Alector.
Calluna Pharma announced the appointments on 9 October 2024.
Copyright 2024 Evernow Publishing Ltd.